The NICB has received over €34.4 research funding from the HEA under the PRTLI Cycle 3 scheme, and has also received funding from SFI, Atlantic Philanthropies, Enterprise Ireland and the Health Research Board. The NICB occupies a unique niche in Ireland's R&D sector in the Irish third-level biomedical sector, applying molecular cell biology research to solving biomedical problems.
The centre, under the Directorship of Professor Martin Clynes, collaborates with a number of Dublin hospitals in the diagnosis and treatment of cancer, diabetes, eye disease and microbial diseases.
The NICB's first cancer drug treatment discovery has been taken into clinical trial with Professor John Crown in St Vincent's Hospital, Dublin. A team of researchers involved in research into resistance to chemotherapy drugs have identified a common arthritis drug, Sulindac, which can inhibit an important cancer resistance factor. Having successfuly completed Phase I of its clinical evaluation, Phase II is currently underway, examining the role of Sulindac in the improvement of the treatment of malignant melanoma. The trial represents the close partnership of scientists in the NICB, clinical researchers and clinicians, the All-Ireland Cooperative Oncology Group and the pharmaceutical industry.
"Although still in the early stages, this unique partnership is a model for the evolution of rational cancer treatment to improve treatments for Irish cancer patients", said Professor Martin Clynes.
Another research project includes the identification of molecular markers which are present in the blood which are indicative of the presence of a cancer and how the cancer is progressing. This new approach, if translated to the clinic, would mean that a standard blood test would allow the clinician to make early diagnosis of cancer even before the onset of systems. Cancers being investigated include breast, lung, pancreatic, renal and skin cancers.
The treatment of corneal blindness is the subject of another research project carried out by the NICB, the Royal Victoria Eye and Ear Hospital, the Irish Blood Transfusion Service and the Blond McIndoe Centre, in the UK. They are examining the molecular markers of corneal stem cells which can be 'grown' in the lab and used to treat a number of corneal diseases and injuries.
The NICB is also involved in a revolutionary new treatment for diabetes which will involve the harvesting of 'islets' from donors and transplanting them directly into the veins patients. These islets then produce insulin normally, bringing about an effective cure to the patients.
As a result of its expertise in mammalian cell culture technology, NICB is also involved in close collaboration with industry, including an SFI-funded €4m collaborative project with Wyeth Biopharma.
Shane Kenny | alfa
Embryonic development: How do limbs develop from cells?
18.05.2018 | Humboldt-Universität zu Berlin
Reading histone modifications, an oncoprotein is modified in return
18.05.2018 | American Society for Biochemistry and Molecular Biology
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.
Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...
A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.
Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
18.05.2018 | Power and Electrical Engineering
18.05.2018 | Information Technology
18.05.2018 | Information Technology